Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients

DSpace/Manakin Repository

Show simple item record Aung, K. J. Van Deun, A. Declercq, E. Sarker, M. R. Das, P. K. Hossain, M. A. Rieder, H. L. 2014-12-03T15:42:14Z 2014-12-03T15:42:14Z 2014
dc.identifier.issn 1027-3719
dc.identifier.other ITG-B2A
dc.identifier.other DBM
dc.identifier.other U-MYCOB
dc.identifier.other JIF
dc.identifier.other DOI
dc.identifier.other Abstract
dc.identifier.other UPD57
dc.description.abstract SETTING: Tuberculosis (TB) program, Damien Foundation Projects, Bangladesh. OBJECTIVE: To summarize the outcome and its determinants of the first treatment for multidrug-resistant TB using a standardized regimen consisting of a minimum 9 months. DESIGN: This was a prospective, observational study of a gatifloxacin (GFX) based directly observed regimen, mainly with initial hospitalization. The 4-month intensive phase was extended until sputum smear conversion. Patients were monitored using culture for up to 2 years after treatment completion. RESULTS: Of the 515 patients who met the study inclusion criteria and were successively enrolled from 2005 to 2011, 84.4% had a bacteriologically favorable outcome. Due to extensive disease with delayed sputum conversion, only half of the patients completed treatment within 9 months; however, 95% were able to complete treatment within 12 months. Eleven patients failed or relapsed, and 93.1% of the 435 patients who were successfully treated completed at least 12 months post-treatment follow-up. The strongest risk factor for a bacteriologically unfavorable outcome was high-level fluoroquinolone (FQ) resistance, particularly when compounded by initial pyrazinamide (PZA) resistance. Low-level FQ resistance had no unfavorable effect on treatment outcome. Amplification of drug resistance occurred only once, in a patient strain that was initially only susceptible to kanamycin and clofazimine. CONCLUSION: The excellent outcome of the Bangladesh regimen was largely maintained. Bacteriological treatment failures and relapses were rare, except among patients with high-level GFX resistance, notably in the presence of PZA resistance. en_US
dc.language English en_US
dc.subject Bacterial diseases en_US
dc.subject Tuberculosis en_US
dc.subject Mycobacterium tuberculosis en_US
dc.subject Multidrug resistance en_US
dc.subject Treatment outcomes en_US
dc.subject Regimens en_US
dc.subject Hospitalization en_US
dc.subject Sputum smear en_US
dc.subject Conversion en_US
dc.subject Monitoring en_US
dc.subject Standardization en_US
dc.subject Fluoroquinolones en_US
dc.subject Pyrazinamide en_US
dc.subject Bangladesh en_US
dc.subject Asia, South en_US
dc.title Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients en_US
dc.type Article en_US
dc.citation.issue 10 en_US
dc.citation.jtitle International Journal of Tuberculosis and Lung Disease en_US
dc.citation.volume 18 en_US
dc.citation.pages 1180-1187 en_US
dc.citation.jabbreviation Int J Tuberc Lung Dis en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record